MON-528 Defining Optimal Weight Management Goals for Remission in Adolescent Type 2 Diabetes Mellitus

Abstract Disclosure: E. Joo: None. J. Lee: None. M. Yoo: None. J. Park: None. S. Kim: None. Introduction: Longer duration of illness and higher risk of chronic complications are main concern of adolescents with T2DM compared to adult-onset diabetes. Recently DM remission is emerging issue, which defined as a sustained reduction of HbA1c to below 6.5% that persist after withdrawal of glucose-lowering pharmacotherapy over 1 year. This concept holds critical importance in adolescent T2DM, as achieving remission could mitigate long-term complications and improve quality of life. Weight reduction is one of main factor in adult T2DM remission. However, as weight loss goals for obesity management differ between adults and children, it might be also different that body weight approach for remission in adults and adolescents. Therefore, this study aims to evaluate the weight change and other factors influencing T2DM remission in adolescents. Methods: A retrospective cohort analysis was conducted on adolescent patients who diagnosed with T2DM between the age of 10 and 18 from January 2019 to June 2023 at Inha University Hospital. Data collectd on demographics, family history, BMI, HbA1c levels change, lipid profile, hypertension, blood pressure, treatment modality. We compared the patients who maintained remission for more than a year with those who sustained HbA1c level above 6.5% with continuous pharmacological therapy and HbA1c > 6.5%. Patients were excluded if they were on steroid medication, had thyroid disorders, were taking psychiatric medications, or had syndromes associated with diabetes. Result: the study included 14 patients of sustained remission and 32 patients without remission. Mean age of diagnosis was 14.3 years old, duration of follow up was 2.5 years. There were no differences in age, BMI, HbA1c, hyperlipidemia, fatty liver, c-peptide level at diagnosis. Remission group showed no significant change of BMI after 1years, whereas non- remission group experienced an increase in BMI (0.0%±6.4 6.8%±11.0 p =0.036). Hypertension was absent in the remission group, wherea 34.4%(n=11) of non-remission group had hypertension (fisher exact test, p= 0.020). Duration of insulin treatment was longer in the non-remission group (1.8±0.6 month vs 13.8±3.0month, p<0.01), but time of first metformin discontinuation trial was similar between group ( 10.3±5.6 vs 10.6±16.8, p=0.925). longer insulin treatment therapy makes increase BMI at 1year ( r=0.355 p=0.015) Conclusion: Longer insulin treatment duration, comorbidity of hypertension, increase of BMI are negative predictable factors for remission of T2DM in adolescents. Presentation: Monday, July 14, 2025